8.52012

Fmoc-Lys(Boc)-OH

Novabiochem^®

• 别名: Fmoc-Lys(Boc)-OH, N-α-Fmoc-N-ε-t.-Boc-L-lysine
• 经验公式（希尔记法）: C₂₆H₃₂N₂O₆
• CAS号: 71989-26-9
• 分子量: 468.54
• MDL號碼: MFCD00037138
• 分類程式碼代碼: 12352209
• 酶委員會索引編號: 276-256-4
• NACRES: NA.22

属性

• 品質等級: 400
• 產品線: Novabiochem^®
• 化驗: ≥98% (TLC); ≥98.0% (acidimetric); ≥99.0% (HPLC)
• 形狀: powder
• 反應適用性: reaction type: Fmoc solid-phase peptide synthesis
• 製造商／商標名: Novabiochem^®
• mp: 123-130 °C
• 應用: peptide synthesis
• 官能基: Boc; amine
• 儲存溫度: 2-30°C
• InChI: 1S/C26H32N2O6/c1-26(2,3)34-24(31)27-15-9-8-14-22(23(29)30)28-25(32)33-16-21-19-12-6-4-10-17(19)18-11-5-7-13-20(18)21/h4-7,10-13,21-22H,8-9,14-16H2,1-3H3,(H,27,31)(H,28,32)(H,29,30)
• InChI 密鑰: UMRUUWFGLGNQLI-UHFFFAOYSA-N

说明

一般說明

High purity Fmoc-protected amino acid for research and process production of peptides, with very low levels of dipeptide, free-amino acids and acetic acid impurities. Standard building block for introduction of lysine amino-acid residues by Fmoc SPPS

Associated Protocols and Technical Articles
Fmoc-amino acids for Peptide Production
Cleavage and Deprotection Protocols for Fmoc SPPS

應用

• Pharmacokinetics of Tizanidine in Muscle Spasticity: A comprehensive review on Tizanidine covers its pharmacological advancements and therapeutic applications, particularly focusing on muscle spasticity. This highlights the relevance of high-purity Tizanidine-D₄ hydrochloride in creating precise and reproducible pharmacokinetic profiles (Zhu et al., 2024).


• Stable Isotope-Labeled Tizanidine for Bioanalytical Method Development: The development and validation of bioanalytical methods for monitoring drug interactions and metabolism extensively utilize Tizanidine-D₄ HCl. The isotopic labeling aids in accurate quantification and identification, enhancing the reliability of pharmacokinetic and pharmacodynamic studies (Chen et al., 2024).


• Tizanidine-D₄ Hydrochloride Solution for Receptor Binding Studies: The application of Tizanidine-D₄ in receptor binding studies is inferred from research exploring its withdrawal effects and the pharmacological interventions required, suggesting its utility in detailed receptor interaction studies in clinical settings (Tanimura et al., 2024).

聯結

Replaces: 04-12-1026

分析報告

Colour (visual): white to off white
Appearance of substance (visual): powder
Colour index (0,5 M in DMF): ≤ 150 Hazen
Identity (IR): passes test
Enantiomeric purity: ≥ 99.8 % (a/a)
Purity (HPLC): ≥ 99.0 % (a/a)
Fmoc-ß-Ala-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-ß-Ala-Lys(Boc)-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-Lys(Boc)-Lys(Boc)-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-Lys-OH (HPLC): ≤ 0.1 % (a/a)
Assay free amino acid (GC): ≤ 0.2 %
Purity (TLC(011A)): ≥ 98 %
Purity (TLC(0811)): ≥ 98 %
Solubility (25 mmole in 50 ml DMF): clearly soluble
Assay (acidimetric): ≥ 98.0 %
Water (K. F.): ≤ 2.0 %
Ethyl acetate (HS-GC): ≤ 0.5 %
Acetate (IC): ≤ 0.02 %

To see the solvent systems used for TLC of Novabiochem^® products please click here.

法律資訊

Novabiochem is a registered trademark of Merck KGaA, Darmstadt, Germany

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable